10X Historical Balance Sheet

TXG Stock

USD 15.90 0.42 2.71%

Trend analysis of 10X Genomics balance sheet accounts such as Total Current Liabilities of 94.9 M, Total Stockholder Equity of 501.4 M, Other Liabilities of 5.3 M or Net Tangible Assets of 939.9 M provides information on 10X Genomics' total assets, liabilities, and equity, which is the actual value of 10X Genomics to its prevalent stockholders. By breaking down trends over time using 10X Genomics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining 10X Genomics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether 10X Genomics is a good buy for the upcoming year.

10X Genomics Inventory

43.05 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

About 10X Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of 10X Genomics at a specified time, usually calculated after every quarter, six months, or one year. 10X Genomics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of 10X Genomics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which 10X currently owns. An asset can also be divided into two categories, current and non-current.

10X Genomics Balance Sheet Chart

At this time, 10X Genomics' Cash is most likely to increase significantly in the upcoming years. The 10X Genomics' current Cash And Short Term Investments is estimated to increase to about 409.6 M, while Short and Long Term Debt Total is projected to decrease to roughly 63.7 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of 10X Genomics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in 10X Genomics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on 10X Genomics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of 10X Genomics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from 10X Genomics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into 10X Genomics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.At this time, 10X Genomics' Cash is most likely to increase significantly in the upcoming years. The 10X Genomics' current Cash And Short Term Investments is estimated to increase to about 409.6 M, while Short and Long Term Debt Total is projected to decrease to roughly 63.7 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	82.0M	95.2M	95.4M	63.7M
Total Assets	1.0B	1.0B	965.1M	746.1M

Short Long Term Debt Total Total Assets

10X Genomics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets
Total Assets		0.96	0.98	0.99	1.0	0.2	0.97	0.9	0.75	-0.81	-0.91	0.81	0.87	0.94	0.29	0.5	0.78	0.95	0.92	0.97	1.0	0.78	-0.74	0.95	0.91	0.88
Short Long Term Debt Total	0.96		0.94	0.98	0.94	0.05	0.93	0.97	0.81	-0.65	-0.95	0.86	0.74	0.98	0.1	0.3	0.79	0.84	0.99	0.91	0.95	0.79	-0.61	0.95	0.98	0.8
Other Current Liab	0.98	0.94		0.99	0.98	0.11	0.95	0.87	0.71	-0.82	-0.91	0.72	0.88	0.9	0.2	0.56	0.76	0.95	0.89	0.93	0.97	0.76	-0.73	0.94	0.88	0.94
Total Current Liabilities	0.99	0.98	0.99		0.98	0.11	0.96	0.93	0.78	-0.75	-0.94	0.79	0.83	0.95	0.19	0.47	0.78	0.92	0.94	0.95	0.98	0.78	-0.71	0.96	0.93	0.88
Total Stockholder Equity	1.0	0.94	0.98	0.98		0.18	0.97	0.89	0.72	-0.82	-0.89	0.79	0.88	0.93	0.3	0.52	0.71	0.95	0.9	0.97	0.99	0.71	-0.8	0.94	0.9	0.88
Other Liab	0.2	0.05	0.11	0.11	0.18		0.12	-0.05	-0.04	-0.39	0.04	0.25	0.35	0.07	0.95	0.55	0.5	0.31	0.03	0.34	0.23	0.5	0.08	0.05	-0.03	0.05
Net Tangible Assets	0.97	0.93	0.95	0.96	0.97	0.12		0.88	0.85	-0.78	-0.96	0.77	0.85	0.92	0.23	0.45	0.71	0.92	0.9	0.96	0.97	0.71	-0.78	0.99	0.89	0.85
Property Plant And Equipment Net	0.9	0.97	0.87	0.93	0.89	-0.05	0.88		0.82	-0.49	-0.92	0.88	0.59	0.99	0.03	0.14	0.67	0.73	0.99	0.85	0.9	0.67	-0.64	0.91	1.0	0.67
Current Deferred Revenue	0.75	0.81	0.71	0.78	0.72	-0.04	0.85	0.82		-0.42	-0.94	0.7	0.52	0.82	-0.01	0.09	0.64	0.6	0.84	0.76	0.76	0.64	-0.51	0.9	0.8	0.54
Net Debt	-0.81	-0.65	-0.82	-0.75	-0.82	-0.39	-0.78	-0.49	-0.42		0.62	-0.41	-0.99	-0.57	-0.49	-0.8	-0.64	-0.94	-0.56	-0.82	-0.81	-0.64	0.67	-0.71	-0.52	-0.9
Retained Earnings	-0.91	-0.95	-0.91	-0.94	-0.89	0.04	-0.96	-0.92	-0.94	0.62		-0.77	-0.71	-0.93	-0.01	-0.26	-0.73	-0.8	-0.94	-0.88	-0.91	-0.73	0.64	-0.99	-0.92	-0.78
Accounts Payable	0.81	0.86	0.72	0.79	0.79	0.25	0.77	0.88	0.7	-0.41	-0.77		0.51	0.91	0.28	0.05	0.71	0.65	0.89	0.78	0.82	0.71	-0.45	0.78	0.9	0.46
Cash	0.87	0.74	0.88	0.83	0.88	0.35	0.85	0.59	0.52	-0.99	-0.71	0.51		0.67	0.44	0.76	0.7	0.97	0.65	0.88	0.87	0.7	-0.7	0.79	0.62	0.92
Non Current Assets Total	0.94	0.98	0.9	0.95	0.93	0.07	0.92	0.99	0.82	-0.57	-0.93	0.91	0.67		0.16	0.23	0.72	0.79	0.99	0.91	0.95	0.72	-0.67	0.93	0.99	0.7
Non Currrent Assets Other	0.29	0.1	0.2	0.19	0.3	0.95	0.23	0.03	-0.01	-0.49	-0.01	0.28	0.44	0.16		0.62	0.39	0.41	0.08	0.44	0.33	0.39	-0.19	0.13	0.04	0.13
Other Assets	0.5	0.3	0.56	0.47	0.52	0.55	0.45	0.14	0.09	-0.8	-0.26	0.05	0.76	0.23	0.62		0.48	0.7	0.19	0.56	0.51	0.48	-0.43	0.36	0.15	0.68
Long Term Debt	0.78	0.79	0.76	0.78	0.71	0.5	0.71	0.67	0.64	-0.64	-0.73	0.71	0.7	0.72	0.39	0.48		0.74	0.76	0.78	0.77	1.0	-0.18	0.73	0.69	0.65
Cash And Short Term Investments	0.95	0.84	0.95	0.92	0.95	0.31	0.92	0.73	0.6	-0.94	-0.8	0.65	0.97	0.79	0.41	0.7	0.74		0.77	0.93	0.94	0.74	-0.74	0.87	0.75	0.94
Net Receivables	0.92	0.99	0.89	0.94	0.9	0.03	0.9	0.99	0.84	-0.56	-0.94	0.89	0.65	0.99	0.08	0.19	0.76	0.77		0.89	0.93	0.76	-0.59	0.93	0.99	0.7
Common Stock Total Equity	0.97	0.91	0.93	0.95	0.97	0.34	0.96	0.85	0.76	-0.82	-0.88	0.78	0.88	0.91	0.44	0.56	0.78	0.93	0.89		0.99	0.78	-0.74	0.92	0.86	0.81
Common Stock Shares Outstanding	1.0	0.95	0.97	0.98	0.99	0.23	0.97	0.9	0.76	-0.81	-0.91	0.82	0.87	0.95	0.33	0.51	0.77	0.94	0.93	0.99		0.77	-0.75	0.95	0.91	0.85
Long Term Debt Total	0.78	0.79	0.76	0.78	0.71	0.5	0.71	0.67	0.64	-0.64	-0.73	0.71	0.7	0.72	0.39	0.48	1.0	0.74	0.76	0.78	0.77		-0.18	0.73	0.69	0.65
Non Current Liabilities Total	-0.74	-0.61	-0.73	-0.71	-0.8	0.08	-0.78	-0.64	-0.51	0.67	0.64	-0.45	-0.7	-0.67	-0.19	-0.43	-0.18	-0.74	-0.59	-0.74	-0.75	-0.18		-0.72	-0.63	-0.7
Capital Surpluse	0.95	0.95	0.94	0.96	0.94	0.05	0.99	0.91	0.9	-0.71	-0.99	0.78	0.79	0.93	0.13	0.36	0.73	0.87	0.93	0.92	0.95	0.73	-0.72		0.91	0.82
Inventory	0.91	0.98	0.88	0.93	0.9	-0.03	0.89	1.0	0.8	-0.52	-0.92	0.9	0.62	0.99	0.04	0.15	0.69	0.75	0.99	0.86	0.91	0.69	-0.63	0.91		0.69
Other Current Assets	0.88	0.8	0.94	0.88	0.88	0.05	0.85	0.67	0.54	-0.9	-0.78	0.46	0.92	0.7	0.13	0.68	0.65	0.94	0.7	0.81	0.85	0.65	-0.7	0.82	0.69

Click cells to compare fundamentals

10X Genomics Account Relationship Matchups

10X Genomics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	605.9M	929.3M	1.0B	1.0B	965.1M	746.1M
Short Long Term Debt Total	29.7M	63.0M	82.0M	95.2M	95.4M	63.7M
Other Current Liab	36.8M	88.4M	72.8M	79.3M	70.2M	58.9M
Total Current Liabilities	63.0M	118.1M	110.4M	131.0M	127.2M	94.9M
Total Stockholder Equity	420.1M	739.1M	817.6M	805.7M	741.0M	501.4M
Other Liab	103.0M	15.1M	14.1M	6.1M	5.5M	5.3M
Net Tangible Assets	397.7M	739.1M	787.7M	778.4M	895.1M	939.9M
Property Plant And Equipment Net	48.8M	119.8M	230.4M	359.2M	344.9M	176.2M
Current Deferred Revenue	3.3M	4.5M	5.3M	7.9M	13.2M	13.8M
Net Debt	(394.4M)	(600.6M)	(505.5M)	(124.6M)	(263.9M)	(277.1M)
Retained Earnings	(262.4M)	(805.1M)	(863.3M)	(1.0B)	(1.3B)	(1.2B)
Accounts Payable	13.0M	4.7M	17.4M	21.6M	15.7M	13.6M
Cash	424.2M	663.6M	587.4M	219.7M	359.3M	372.0M
Non Current Assets Total	125.1M	155.0M	271.2M	393.9M	369.1M	210.6M
Non Currrent Assets Other	76.3M	12.8M	10.9M	7.4M	3.1M	2.9M
Other Assets	53.9M	82.1M	10.9M	7.4M	8.5M	8.0M
Cash And Short Term Investments	424.2M	663.6M	587.4M	430.0M	388.7M	409.6M
Net Receivables	33.4M	51.2M	85.3M	104.2M	114.8M	67.9M
Common Stock Shares Outstanding	78.2M	101.2M	110.3M	113.9M	117.2M	85.8M
Liabilities And Stockholders Equity	605.9M	929.3M	1.0B	1.0B	965.1M	746.1M
Non Current Liabilities Total	122.8M	72.1M	90.9M	92.3M	96.9M	108.9M
Capital Surpluse	682.5M	1.5B	1.7B	1.8B	2.1B	2.2B
Inventory	15.3M	30.0M	60.0M	81.6M	73.7M	43.0M
Other Current Assets	8.0M	42.6M	28.8M	19.2M	18.8M	19.3M
Other Stockholder Equity	76.6M	1.5B	1.7B	1.8B	2.0B	1.1B
Total Liab	185.8M	190.3M	201.3M	223.2M	224.1M	178.0M
Net Invested Capital	449.8M	739.1M	817.6M	805.7M	741.0M	512.4M
Property Plant And Equipment Gross	48.8M	72.8M	230.4M	359.2M	448.4M	470.8M
Total Current Assets	480.8M	774.4M	747.6M	635.0M	596.0M	535.6M
Accumulated Other Comprehensive Income	(46K)	(50K)	22K	(4.3M)	(429K)	(450.5K)
Non Current Liabilities Other	1.1M	72.1M	90.9M	6.1M	4.3M	4.1M
Net Working Capital	417.8M	656.2M	637.2M	504.1M	468.9M	440.6M
Short Term Debt	9.9M	11.9M	10.3M	18.1M	23.0M	12.8M
Property Plant Equipment	48.8M	72.8M	230.4M	289.3M	332.7M	349.4M

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:

How To Invest In 10X

Details

Is 10X Stock a good investment?

Details

What is 10X Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.52)

Revenue Per Share

5.261

Quarterly Revenue Growth

(0.01)

Return On Assets

(0.11)

Return On Equity

(0.25)

The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

10X Historical Balance Sheet

10X Genomics Inventory

43.05 Million

About 10X Balance Sheet Analysis

10X Genomics Balance Sheet Chart

Total Assets

Total Current Liabilities

10X Genomics balance sheet Correlations

10X Genomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

10X Genomics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accumulated Amortization	Total Assets
Short Long Term Debt Total	Other Current Liab
Total Current Liabilities	Total Stockholder Equity
Other Liab	Net Tangible Assets
Property Plant And Equipment Net	Total Permanent Equity
Warrants	Current Deferred Revenue
Noncontrolling Interest In Consolidated Entity	Net Debt
Retained Earnings	Accounts Payable
Cash	Non Current Assets Total
Non Currrent Assets Other	Other Assets
Long Term Debt	Cash And Short Term Investments
Net Receivables	Good Will
Common Stock Total Equity	Retained Earnings Total Equity
Common Stock Shares Outstanding	Short Term Investments
Long Term Debt Total	Liabilities And Stockholders Equity
Non Current Liabilities Total	Capital Surpluse
Capital Lease Obligations	Negative Goodwill
Inventory	Other Current Assets
Other Stockholder Equity	Total Liab
Additional Paid In Capital	Deferred Long Term Liab
Net Invested Capital	Preferred Stock Redeemable
Long Term Investments	Property Plant And Equipment Gross
Short Long Term Debt	Preferred Stock Total Equity
Total Current Assets	Accumulated Other Comprehensive Income
Treasury Stock	Non Current Liabilities Other
Accumulated Depreciation	Net Working Capital
Deferred Long Term Asset Charges	Short Term Debt
Intangible Assets	Common Stock
Temporary Equity Redeemable Noncontrolling Interests	Property Plant Equipment
Capital Stock

Total Stockholder Equity	+ 1.0	Total Assets
Common Stock Shares Outstanding	+ 1.0	Total Assets
Inventory	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Current Liabilities	+ 0.99	Total Assets
Net Receivables	+ 0.99	Short Long Term Debt Total

Capital Surpluse	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Retained Earnings	- 0.96	Net Tangible Assets
Retained Earnings	- 0.95	Short Long Term Debt Total
Net Receivables	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.94	Net Debt